drugset / Trial / NCT02372149
IVIg for Demyelination in Diabetes Mellitus
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether intravenous immunoglobulin (IVIg) is an effective intervention for patients with diabetes, peripheral neuropathy, and demyelination on nerve conduction studies. All patients will receive both IVIg and placebo for 3 months each, with a 3 month washout period in between.
Timeline
- Start
- 2015-02
- Primary completion
- 2018-02
- Completion
- 2018-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | 1 mg/kg | Intravenous |